This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Inclusion Criteria:
- Pathologically-confirmed diagnosis of NHL or RCC
- Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy
- Confirmed CD70 expression
- Measurable disease, defined as at least 1 lesion >1.5 cm in the greatest transverse diameter for patients with NHL, and at least 1 non-resectable tumor lesion > or equal to 10 mm in diameter for patients with RCC
Exclusion Criteria:
- Previously received an allogeneic transplant
- History of another primary malignancy that has not been in remission for at least 3 years
- Prior anti-CD70-directed therapy
Last updated: 07/20/2012
NCT ID: NCT01015911
IRB Number:09-005177
Find Mayo Clinic on